Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?

Anti-cancer drugs - 1 Nov 2020

Malentacchi Francesca, Turrini Irene, Zepponi Francesca, Fantappiè Giulia, Sorbi Flavia, Antonuzzo Lorenzo, Fambrini Massimiliano, Noci Ivo, Pillozzi Serena

Abstract excerpt

Endometrial cancer is the commonest gynecological cancer, the majority is endometrioid type, diagnosed at an early stage with 69-88% 5-year survival. Low-grade endometrial cancers have low recurrence rates and often do not receive adjuvant therapy; however, a subset of these patients will have poor outcomes and would benefit from adjuvant treatment has been challenging. We evaluate the circulating cell-free DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Neoplasm Recurrence, Local

Source

Identifiers

PMID: 32568830
DOI: 10.1097/CAD.0000000000000963

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?PMID 32568830Read ↗

Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and ProgressionSemantic proximity Read ↗

ROLE OF cfDNA AND ctDNA TO IMPROVE THE RISK STRATIFICATION AND THE DISEASE FOLLOW-UP IN PATIENTS WITH ENDOMETRIAL CANCER: TOWARDS THE CLINICAL APPLICATIONSemantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancerSemantic proximity Read ↗

Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.Semantic proximity Read ↗

Utility of circulating tumor DNA for detection and monitoring of endometrial cancer recurrence and progressionSemantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.Semantic proximity Read ↗

Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.Semantic proximity Read ↗

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.Semantic proximity Read ↗

Sensitive Detection of Gynecological Cancer Recurrence Using Circulating Tumor DNA and Digital PCR: A Comparative Study with Serum Biochemical Markers.Semantic proximity Read ↗

Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.Semantic proximity Read ↗

Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.